Novo Nordisk A/S (NYSE: NVO) CEO Mike Doustdar told Reuters on August 13, 2026, that investors are significantly underestimating how much the obesity drug market will fragment as new treatments arrive.
Doustdar pushed back firmly against the Wall Street narrative that Novo and Eli Lilly and Company (NYSE: LLY) are locked in a zero-sum battle for a single, shrinking pool of patients.
Novo’s market value has fallen sharply since its 2024 peak, while Lilly’s has climbed past $1 trillion, giving investors reason to frame this rivalry as one company winning directly at the other’s expense.
Doustdar argued the market will not be “Coke versus Pepsi. It will be Coke and Pepsi and Fanta and Dr Pepper and Red Bull,” suggesting patients will sort themselves across many differentiated GLP-1 treatment options.
He pointed to Novo’s oral Wegovy pill, which already holds a 90% share of the oral GLP-1 market, citing data showing better weight-loss outcomes than Lilly’s competing Foundayo pill.
Lilly’s CEO drew a comparison between his ambitions for the obesity portfolio and Novo’s own insulin business, where the company sells half the world’s insulin supply across 12 different brands rather than one dominant product.
Novo’s next-generation obesity drug CagriSema delivered an average body weight reduction of 23% in trials, falling short of the more than 25% weight loss recorded with Lilly’s Zepbound treatment.
Doustdar openly acknowledged that CagriSema “has been written off pretty much by all investors,” a candid admission that reflects the pressure Novo faces heading into the next competitive cycle.
The obesity market both companies are competing in is expected to surpass $100 billion annually by 2030, according to analyst estimates, meaning even modest shifts in market share carry enormous financial consequences.
Lilly’s Zepbound currently outperforms CagriSema on weight-loss data, and the company’s rising market capitalization signals that investors continue to favor Lilly’s execution over Novo’s broader segmentation argument.
Hedge fund interest in Eli Lilly and Company (NYSE: LLY) stood at 132 holders as of Q1 2026, down from 137 the prior quarter, while Novo Nordisk A/S (NYSE: NVO) held steady at 55 hedge fund holders.
Doustdar’s insulin-market comparison carries a cautionary undertone: if new rivals fracture the obesity market the way competition reshaped Novo’s diabetes business, Lilly’s current premium valuation could come under significant pressure.
The central question is whether Doustdar’s segmentation thesis reflects a genuine read on the market’s direction or represents the kind of argument a CEO makes when his company’s stock is underperforming a rival.
For now, Lilly’s stock price and market capitalization suggest that Wall Street has not yet accepted the soda-aisle model of obesity drug competition that Novo’s leadership is promoting.
